Gasior M, Carter R B, Goldberg S R, Witkin J M
Preclinical Pharmacology Laboratory, Addiction Research Center, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland 21224, USA.
J Pharmacol Exp Ther. 1997 Aug;282(2):543-53.
Epilepsy continues to be a significant clinical problem as current medications neither adequately control seizures nor are free of untoward side-effects. Modulation of the neuroactive steroid site on the gamma-aminobutyric acid (GABA)A receptor complex may be an important new direction for pharmaceutical interventions in epilepsy. In this study we evaluated the protective actions of four neuroactive steroids, 3alpha-hydroxy-5alpha-pregnan-20-one, the 3beta-methylated analog, ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), 3alpha-hydroxy-5beta-pregnan-20-one and Co 2-1068 (3beta-(4acetylphenyl)ethynyl-3alpha,21-dihydroxy-5beta++ +-20-one-21-hemisuccinate), against several standard convulsive tests in male, Swiss-Webster mice. Consistent with their GABAergic actions, the neuroactive steroids as well as diazepam and phenobarbital dose-dependently protected against clonic convulsions induced by pentylenetetrazol; the N-methyl-D-aspartate receptor antagonist, dizocilpine, was ineffective. In contrast to diazepam and phenobarbital, however, all of the neuroactive steroids and dizocilpine produced full protection against cocaine-induced convulsions. Some of the neuroactive steroids, as well as dizocilpine, were efficacious against the seizures and lethality induced by N-methyl-D-aspartate. Pregnenolone, a steroid devoid of GABAergic activity, was not effective in any of the convulsant models. Although all of the compounds produced motor toxicity in high doses as measured by the inverted-screen test, the neuroactive steroids demonstrated an equivalent or improved separation between anticonvulsant potency and motoric impairment. Inactive doses of the neuroactive steroids markedly enhanced the anticonvulsant effects of diazepam against pentylenetetrazol without significantly increasing motor toxicity. This adjunct treatment resulted in protective indices ranging from 60 to 360 compared to 12 for diazepam alone. The distinct profile of anticonvulsant activity of the neuroactive steroids may be related to their combined actions on gamma-aminobutyric acid, N-methyl-D-aspartate receptors, or voltage-operated Ca++ channels. These results help to define the neuroactive steroids as a novel class of antiepileptic agents and suggest their potential in clinical practice.
癫痫仍然是一个重大的临床问题,因为目前的药物既不能充分控制癫痫发作,也并非没有不良副作用。调节γ-氨基丁酸(GABA)A受体复合物上的神经活性甾体位点可能是癫痫药物干预的一个重要新方向。在本研究中,我们评估了四种神经活性甾体3α-羟基-5α-孕烷-20-酮、其3β-甲基化类似物甘氨酰环烷酮(3α-羟基-3β-甲基-5α-孕烷-20-酮)、3α-羟基-5β-孕烷-20-酮和Co 2-1068(3β-(4-乙酰苯基)乙炔基-3α,21-二羟基-5β-20-酮-21-半琥珀酸酯)对雄性瑞士韦伯斯特小鼠几种标准惊厥试验的保护作用。与它们的GABA能作用一致,神经活性甾体以及地西泮和苯巴比妥对戊四氮诱导的阵挛性惊厥具有剂量依赖性保护作用;N-甲基-D-天冬氨酸受体拮抗剂地佐环平无效。然而,与地西泮和苯巴比妥不同的是,所有神经活性甾体和地佐环平均对可卡因诱导的惊厥具有完全保护作用。一些神经活性甾体以及地佐环平对N-甲基-D-天冬氨酸诱导的癫痫发作和致死率有效。孕烯醇酮是一种缺乏GABA能活性的甾体,在任何惊厥模型中均无效。尽管所有化合物在高剂量时通过倒屏试验测量均产生运动毒性,但神经活性甾体在抗惊厥效力和运动障碍之间表现出同等或更好的区分度。神经活性甾体的无活性剂量显著增强了地西泮对戊四氮的抗惊厥作用,而没有显著增加运动毒性。与单独使用地西泮时的保护指数12相比,这种辅助治疗的保护指数范围为60至360。神经活性甾体独特的抗惊厥活性谱可能与其对γ-氨基丁酸、N-甲基-D-天冬氨酸受体或电压门控Ca++通道的联合作用有关。这些结果有助于将神经活性甾体定义为一类新型抗癫痫药物,并提示它们在临床实践中的潜力。